Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults
Public ClinicalTrials.gov record NCT00071851. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IB Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA009-00-VP, Administered at 2 Different Dosing Schedules, in HIV-1-Uninfected Adult Participants
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to test the safety of and immune response to an HIV-1 vaccine, VRC-HIVDNA009-00-VP, in HIV uninfected participants. Two different doses of the vaccine will be tested.
Study identification
- NCT ID
- NCT00071851
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 180 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 50 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2003
- Primary completion
- Not listed
- Completion
- Sep 30, 2005
- Last update posted
- Oct 13, 2021
2003 – 2005
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alabama Vaccine CRS | Birmingham | Alabama | 35294 | — |
| San Francisco Vaccine and Prevention CRS | San Francisco | California | 94102 | — |
| Project Brave HIV Vaccine CRS | Baltimore | Maryland | 21201 | — |
| Johns Hopkins Bloomberg School of Public Health,Ctr for Immunization Research,Project SAVE-Baltimore | Baltimore | Maryland | 21205 | — |
| Brigham and Women's Hosp. CRS | Boston | Massachusetts | 02115 | — |
| Fenway Community Health Clinical Research Site (FCHCRS) | Boston | Massachusetts | 02215 | — |
| Saint Louis Univ. School of Medicine, HVTU | St Louis | Missouri | 63110 | — |
| NY Blood Ctr./Union Square CRS | New York | New York | 10003 | — |
| HIV Prevention & Treatment CRS | New York | New York | 10032 | — |
| Univ. of Rochester HVTN CRS | Rochester | New York | 14642 | — |
| NY Blood Ctr./Bronx CRS | The Bronx | New York | 10455 | — |
| Miriam Hospital's HVTU | Providence | Rhode Island | 02906 | — |
| Vanderbilt Vaccine CRS | Nashville | Tennessee | 37232 | — |
| FHCRC/UW Vaccine CRS | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00071851, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 13, 2021 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00071851 live on ClinicalTrials.gov.